According to Spectrum Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -109.76%. At the end of 2018 the company had an Operating Margin of -109.77%.
Year | Operating Margin | Change |
---|---|---|
2018 | -109.77% | 30.43% |
2017 | -84.15% | 74% |
2016 | -48.36% | 56.05% |
2015 | -30.99% | 33.01% |
2014 | -23.30% | -0.88% |
2013 | -23.51% | -179.68% |
2012 | 29.50% | 9.02% |
2011 | 27.06% | -141.03% |
2010 | -65.96% | 26.86% |
2009 | -51.99% | 3.22% |
2008 | -50.37% | -89.61% |
2007 | -484.81% | 6.22% |
2006 | -456.43% | -85.87% |
2005 | -3,231.02% | -34.87% |
2004 | -4,961.24% | 381.44% |
2003 | -1,030.50% | 69.03% |
2002 | -609.67% | -99.11% |
2001 | -68,469.52% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 24.28% | -122.12% | ๐บ๐ธ USA |
![]() Novartis NVS | 16.16% | -114.72% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 29.90% | -127.24% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 16.84% | -115.34% | ๐บ๐ธ USA |
![]() Biogen BIIB | 36.44% | -133.20% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 19.18% | -117.47% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 18.87% | -117.19% | ๐ฌ๐ง UK |
![]() Seagen
SGEN | -42.91% | -60.91% | ๐บ๐ธ USA |
![]() Curis CRIS | -426.66% | 288.72% | ๐บ๐ธ USA |
![]() Teva Pharmaceutical Industries TEVA | 4.14% | -103.77% | ๐ฎ๐ฑ Israel |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.